Microscopy Market Size & Share 2026-2035

Microscopy Market Size

The global microscopy market was valued at USD 10.5 billion in 2025 and is projected to increase from USD 11.2 billion in 2026 to USD 22 billion by 2035, at an approximately 7.8% CAGR.

Unit volumes are expected to expand at a faster 8.2% CAGR, indicating that wider adoption of digital optical and entry-to-mid-tier systems will contribute materially to growth alongside demand for premium electron, confocal, and scanning probe platforms.

Market expansion from USD 8.493 billion in 2022 to USD 10.453 billion in 2025, equivalent to an approximately 7.2% historic CAGR, coincided with laboratory reinvestment, broader cryo-electron microscopy adoption, and sustained pharmaceutical research demand. Thermo Fisher Scientific reported USD 7.463 billion in 2024 Analytical Instruments revenue, including USD 2.186 billion in the fourth quarter, compared with USD 2.037 billion a year earlier ^{[1]Thermo Fisher Scientific, Fourth Quarter and Full Year 2024 Financial Results, February 2025, ir.thermofisher.com}. ZEISS increased group revenue from EUR 10.894 billion in fiscal 2023/24 to EUR 11.896 billion in fiscal 2024/25, while committing EUR 1.731 billion, or about 15% of revenue, to research and development .

Electron microscopy represents 42.34% of 2025 market value, ahead of optical microscopy at 36.97%; scanning probe microscopy accounts for the balance. Electron systems command substantial value because semiconductor metrology, advanced materials analysis, and structural biology workflows require high-resolution instruments, specialized detectors, and application support. Optical platforms retain the broadest installed base across pathology, cell biology, clinical testing, and routine industrial inspection.

Diagnostic centers account for 48.87% of 2025 demand, while academic and research institutions represent 36.92%. Academic and biological research is the largest application segment at 34.8%, valued at USD 3.6 billion, followed by drug discovery and development at 28.4%. North America is the largest regional market, with the U.S. valued at approximately USD 4.0 billion in 2025. Asia Pacific is expected to record the fastest growth, at approximately 8.4% CAGR through 2035.

The forecast therefore depends less on a uniform expansion of laboratory budgets than on the ability of suppliers to convert technical performance into usable throughput. A lower-voltage cryo-EM platform capable of sub-3 Å structure determination can broaden access to advanced structural biology , while optical approaches that reduce photobleaching can make longer intravital studies commercially practical . The principal constraint is that sophisticated systems require skilled operators and validated analysis workflows. Suppliers that reduce training burdens without weakening data quality are positioned to capture demand that might otherwise remain underutilized after installation.

Key Drivers

Increasing Application Areas of Microscopy

Microscopy is becoming more embedded in production and research workflows that cannot be served effectively by bulk analytical techniques. Semiconductor applications require surface-defect review, cross-sectional analysis, and process-control metrology. JEOL identifies semiconductor development, drug discovery, and battery research as priority growth markets, including TEM and focused-ion-beam applications for semiconductor manufacturers in Taiwan and South Korea ^{[3]JEOL Ltd., Integrated Report 2024, 2024, jeol.com}. Hitachi High-Tech similarly supplies CD-SEM systems for semiconductor process control and introduced its SU9600 ultrahigh-resolution SEM in October 2025 .

Life-science demand is also diversifying. Drug-discovery groups use high-content and confocal systems to connect cellular morphology with compound response, while pharmaceutical manufacturers use microscopy to examine formulation homogeneity, contaminants, and material characteristics. WITec's confocal Raman workflow supports non-destructive characterization of pharmaceutical composition and homogeneity, including contaminant detection . The resulting demand is less dependent on one research discipline, which broadens the addressable installed base for instruments, cameras, sample-preparation products, and analysis software.

Technological Advancement in Microscopes

Technical progress is widening the set of experiments that can be performed without moving samples between instruments or sacrificing throughput. A 2025 structural biology study demonstrated sub-3 Å protein structures at 100 keV across specimens ranging from 50 kDa apoferritin to a 3.9 MDa AAV9 capsid . Lower-voltage capability does not eliminate the premium market for advanced systems, but it can lower the capital and facility threshold for laboratories seeking structural-biology capacity.

Optical technologies are extending the practical duration and depth of live imaging. Confocal scanning light-field microscopy demonstrated a 15-fold signal-to-background improvement over spinning-disk confocal microscopy and a two-order-of-magnitude reduction in photobleaching while preserving near-diffraction-limit resolution . ZEISS has also integrated Lightfield 4D capabilities with the LSM 910 and LSM 990 platforms for high-speed volumetric imaging . Such advances raise the commercial importance of workflow automation and analysis software because laboratories gain value only when richer image streams can be acquired, processed, and interpreted without proportionally increasing operator time.

Rising Focus on Nanotechnology and Regenerative Medicine

Nanomaterial-based scaffolds, nanoparticle drug-delivery systems, and stem-cell research require imaging methods that can characterize cell-material interactions across several length scales. Fluorescence and super-resolution imaging are relevant to in vivo stem-cell tracking, while electron and scanning-probe methods support nanoscale material characterization . This work favors suppliers capable of connecting optical, molecular, and ultrastructural information rather than selling isolated instruments.

Bruker's 2024 acquisitions illustrate this convergence. Its purchase of Phasefocus added label-free live-cell imaging for long-term cell tracking and organoid monitoring without fluorescence-associated phototoxicity . The acquisition of Nanophoton added Raman microscopy capabilities for biopharma, advanced materials, semiconductor, and polymer applications ^{[9]Bruker Corporation, Bruker Acquires Nanophoton Corporation, February 2024, ir.bruker.com}. In Europe, the 3DNanoScope4All project is developing a high-performance live-cell nanoscope using light-field microscopy for three-dimensional and structural imaging while preserving cellular integrity . These efforts reinforce demand for systems that support longitudinal biological experiments as well as material-level characterization.

Favourable Funding Scenario for R&D in Microscopy

Grant funding remains central to premium microscopy purchases because many university and medical-center acquisitions are tied to multi-year research programs. NIH awarded approximately USD 35.3 billion in extramural research grants in fiscal 2025, including roughly USD 26.5 billion in research project grants, within an NIH and ARPA-H program level of USD 48.535 billion ^{[7]National Institutes of Health, Fiscal Year 2025 By the Numbers: Extramural Grant Investments in Research, March 2026, grants.nih.gov}. The agency also supported biomolecule-retention expansion microscopy research through an approximately USD 1.789 million award beginning in April 2024 .

European funding is supporting both infrastructure and commercialization. The IMAGINE project, coordinated by EMBL with 25 participants and EUR 5.165 million in EU contribution, combines X-ray imaging, cryo-EM, cryo and dynamic super-resolution microscopy, and large-volume intravital light microscopy with AI-powered image analysis . AOscopy, awarded under the EIC Transition mechanism in April 2025, is developing adaptive-optics-enhanced multiphoton microscopy for deep-tissue imaging through May 2028 . These programs can shorten the path from method development to shared imaging infrastructure, increasing the probability that research-led demand becomes instrument procurement rather than remaining a laboratory prototype.

Key Restraints

Dearth of Skilled Professionals

Sophisticated microscopy is constrained by the availability of personnel able to prepare samples, configure instruments, acquire reproducible images, and conduct quantitative analysis. The American Society for Clinical Pathology found that anatomic pathology had the highest overall vacancy rate, at 28.5%, in its 2024 survey; ten of 17 laboratory departments reported increasing retirements, with retirements outpacing the entry of new professionals . A 2024 laboratory-professional survey likewise identified shortages of highly skilled personnel as the leading professional challenge and cited declining enrollment in four-year clinical laboratory science programs .

The constraint affects market conversion rather than scientific need. A laboratory may obtain capital funding for an advanced electron or confocal system but delay productive deployment when operator training, sample-preparation expertise, or computational support is unavailable. This can lengthen replacement cycles and favor systems with simpler automation, established application protocols, and stronger local service coverage. The effect is particularly material in regions expanding research or diagnostic capacity faster than their specialist workforce.

Availability of Open-Source Microscopy Software

Open-source tools reduce the portion of imaging workflows for which academic users will accept recurring commercial software fees. Fiji, an ImageJ distribution, is available under GNU GPL and BSD 2-Clause licensing and supports cell tracking, three-dimensional reconstruction, fluorescence quantification, particle analysis, batch processing, and extensible plug-ins . The ImageJ ecosystem has become a widely used biological-image-analysis environment, with plug-in capabilities that extend to deep-learning segmentation tools such as StarDist and Cellpose .

This pressure is concentrated in the software component, which represents 17.32% of market value. Commercial suppliers retain an advantage where acquisition control, audit trails, hardware-specific optimization, validated workflows, and service accountability matter, particularly in regulated pharmaceutical and clinical environments. In academic laboratories, however, suppliers must demonstrate operational benefits beyond functions that can be reproduced through open-source packages and in-house scripting.

Training, remote application support, guided acquisition, and automated quality controls can increase the usable capacity of advanced instruments where expertise is scarce. Software vendors, by contrast, need to protect revenue through capabilities that are difficult to replicate in community-developed workflows, including validated compliance functions, instrument-specific performance optimization, and integrated automation. The market's growth outlook remains positive because demand drivers are diversified, but suppliers that fail to address either adoption friction risk losing revenue even in laboratories with strong scientific demand.

Microscopy Market Segment Analysis

By Product

Optical Microscopy

Optical microscopy represents 36.97% of 2025 market value and has the broadest application base across biological research, clinical pathology, industrial inspection, and education. Fluorescence microscopy accounts for 21.5% of the optical segment, while confocal scanning microscopy represents 17.9% and is the fastest-growing optical sub-segment. Upright microscopes account for 14.5%, inverted systems 13.1%, phase-contrast configurations 11.8%, stereomicroscopes 9.8%, and near-field scanning optical microscopy 6.8%.

Confocal growth reflects the migration from two-dimensional cell assays toward thicker, more complex biological models. ZEISS LSM 910 systems with Airyscan are used for three-dimensional drug-screening workflows that require deep optical sectioning and subcellular quantification of drug response ^{[5]Carl Zeiss Microscopy, Revolutionizing Drug Discovery with 3D Microscopy Models, publication date not stated, zeiss.com}. The commercial consequence is a shift toward complete imaging workflows, where environmental control, high-sensitivity cameras, automation, and analysis tools become important alongside the core microscope.

Electron Microscopy

Electron microscopy holds the largest product share at 42.34%. SEM accounts for 54.6% of electron microscopy, and TEM represents 45.4%. SEM remains essential to surface imaging, defect review, compositional analysis, and industrial failure investigation. TEM is gaining momentum in structural biology, nanomaterials, batteries, and advanced semiconductor characterization because these applications require internal structural information at substantially higher resolution.

Bruker's January 2024 acquisition of Nion added aberration-corrected STEM and sub-Angstrom stability capabilities to its portfolio ^{[6]Bruker Corporation, Bruker Acquires Electron Microscopy Company Nion, January 2024, ir.bruker.com}. The acquisition illustrates how competition in electron microscopy is extending beyond base instrument sales toward specialized analytical performance. TEM growth is likely to be concentrated in institutions that can support cryogenic preparation, detector investment, data processing, and highly trained users, rather than distributed evenly across all research laboratories.

Scanning Probe Microscopy

Scanning probe microscopy accounts for the remaining market share and includes AFM, STM, and related surface-characterization modalities. Its demand base spans polymer science, nanomaterials, membrane biophysics, and cell mechanics, with higher-value opportunities emerging from semiconductor metrology. Oxford Instruments reported £252.2 million in Materials & Characterisation revenue for the fiscal year ended March 2024, with 11.4% constant-currency growth; its portfolio includes Asylum Research AFM systems ^{[8]Oxford Instruments plc, Annual Report 2024, 2024, oxinst.com}. The segment benefits where customers need surface topography and nanomechanical information that cannot be obtained through optical or electron imaging alone.

By Component

Microscopes account for 49.12% of market revenue, equivalent to approximately USD 5.2 billion in 2025. Hardware remains the largest value pool because electron, confocal, and high-end scanning-probe platforms carry high capital prices and typically require specialized configurations.

Accessories represent 33.56% of revenue. Cameras, objective lenses, stages, environmental chambers, specimen-preparation products, and detectors provide both installation-related sales and recurring replacement opportunities. Detector upgrades can extend the useful life of an installed instrument, allowing laboratories to improve image quality without committing to a full platform replacement.

Software accounts for 17.32% and is expected to be the fastest-growing component. Its value is highest where it reduces acquisition time, improves reproducibility, enables remote collaboration, or meets regulatory documentation requirements. The component's growth potential is therefore linked to suppliers' ability to establish defensible value beyond open-source image analysis.

By End Use

Drug Discovery and Development

Drug discovery and development accounts for 28.4% of market value. High-content screening, confocal imaging, and multiphoton microscopy support target identification, phenotypic screening, toxicity assessment, and live-cell analysis. Nikon's AX/AX R confocal systems provide a 25 mm field of view, up to 8,192 x 8,192-pixel imaging, and 30-frame-per-second resonant scanning, with BioPipeline integrations for automated liquid handling and plate imaging . The application favors instruments that combine image quality with reproducible automation, since throughput is commercially relevant only when image data can be compared across large compound libraries and complex models.

Clinical Diagnostics

Clinical diagnostics represents 15.2% of application value, or USD 1.6 billion in 2025. Microscopy remains integral to histology, hematology, immunofluorescence, and fluorescence in situ hybridization workflows. Digital pathology and workflow automation create modernization demand, but staffing shortages can limit the productivity gains from new systems. The 28.5% anatomic-pathology vacancy rate reported by ASCP highlights why buyers may value tools that reduce manual handling, standardize image capture, and improve remote-review capability .

Pharmaceutical and Biopharmaceutical Manufacturing

Pharmaceutical and biopharmaceutical manufacturing accounts for 21.6% of market demand. Buyers use microscopy to investigate API characteristics, formulation uniformity, particulate contamination, and drug-delivery-system behavior. Confocal Raman microscopy can characterize pharmaceutical chemical composition and homogeneity with non-destructive spatial resolution . Procurement in this segment is influenced by workflow reliability and documentation requirements as much as image resolution, which supports demand for integrated hardware, validated analysis software, and supplier service capability.

Academic and Biological Research

Academic and biological research represents 34.8% of market value and was valued at USD 3.6 billion in 2025. The segment includes structural biology, neuroscience, developmental biology, cell biology, microbiology, and materials research. U.S. NIH funding provides a substantial procurement base for research infrastructure ^{[7]National Institutes of Health, Fiscal Year 2025 By the Numbers: Extramural Grant Investments in Research, March 2026, grants.nih.gov}, while European initiatives such as IMAGINE are building shared access to advanced imaging technologies . Academic demand drives early adoption of new methods but remains sensitive to grant cycles, shared-facility utilization, and the availability of specialized operators.

The faster 8.2% unit-volume CAGR relative to the 7.8% value CAGR indicates that lower- and mid-priced systems will contribute a growing share of installations, particularly in developing laboratory markets. Premium suppliers cannot rely on technical specifications alone in this environment. They need modular configurations, upgrade paths, and service models that preserve access to cost-sensitive users while retaining differentiated value in drug discovery, semiconductor metrology, and regulated clinical applications.

Microscopy Market Regional Analysis

North America

North America is the largest microscopy market, led by the U.S., which generated approximately USD 4.0 billion in 2025. The region combines strong academic research infrastructure, pharmaceutical research intensity, clinical laboratory modernization, and semiconductor development. NIH's USD 35.3 billion in FY2025 extramural grants provides an important underlying source of demand for research equipment in universities, medical centers, and national laboratories ^{[7]National Institutes of Health, Fiscal Year 2025 By the Numbers: Extramural Grant Investments in Research, March 2026, grants.nih.gov}.

The regional market is favorable for high-value systems because buyers are more likely to maintain shared facilities, application specialists, and service budgets needed to support advanced platforms. Demand nevertheless depends on staffing availability in clinical and academic laboratories. Suppliers that couple instruments with implementation support and validated workflows can improve their position where capital budgets are available but labor capacity is constrained.

Europe

Europe accounted for approximately USD 2.3 billion in 2025. Germany is a major demand and supply center, supported by extensive research infrastructure and ZEISS's global microscopy presence. ZEISS reported EUR 2.334 billion in Industrial Quality & Research revenue in fiscal 2024/25 ^{[2]Carl Zeiss AG, ZEISS Concludes Fiscal Year 2024/25 with Solid Growth, 2025, zeiss.com}. The region's market is strengthened by research collaborations that link instrument development with multi-institutional imaging infrastructure.

United Kingdom demand is supported by university and government research funding and by Oxford Instruments' imaging and analysis portfolio. Oxford Instruments reported total revenue of £470.4 million for the fiscal year ended March 2024, with £142.1 million in Research & Discovery revenue, and cited academic funding as a primary growth driver ^{[8]Oxford Instruments plc, Annual Report 2024, 2024, oxinst.com}. European research projects such as AOscopy and IMAGINE support technology development in deep-tissue, cryogenic, and super-resolution imaging. The opportunity is distributed across national funding systems, making local application support and grant-cycle alignment important for suppliers.

Asia Pacific

Asia Pacific is forecast to expand at approximately 8.4% CAGR, the fastest regional rate. Semiconductor manufacturing, pharmaceutical development, and expanding biomedical research infrastructure are the principal demand sources. Japan, South Korea, Taiwan, and China are particularly important for electron microscopy and semiconductor metrology. JEOL reported JPY 174.3 billion in fiscal 2024 net sales and JPY 27.5 billion in operating profit, while identifying semiconductor development, drug discovery, and battery research as priority markets ^{[3]JEOL Ltd., Integrated Report 2024, 2024, jeol.com}.

Hitachi High-Tech reported JPY 821.7 billion in Measurement & Analysis Systems revenue for the fiscal year ended March 2026 ^{[4]Hitachi High-Tech Corporation, Company Financial Data and Corporate Profile, 2026, hitachi-hightech.com}. Lasertec reported JPY 251.5 billion in net sales for the fiscal year ended June 2025, a 17.8% year-over-year increase, with semiconductor-related products central to performance . These results indicate the scale of the region's advanced inspection ecosystem, although equipment demand can be affected by export controls, customer investment cycles, and the timing of high-NA EUV adoption.

India offers a different growth profile. Pharmaceutical manufacturing, contract research, clinical laboratory development, and academic expansion support volume demand, but price sensitivity and uneven local service infrastructure can limit penetration of highly configured premium systems. Suppliers pursuing Asia Pacific growth must distinguish mature semiconductor-driven markets from high-volume laboratory-expansion markets rather than applying a uniform regional strategy.

Latin America

Brazil and Mexico are the principal regional markets, supported by clinical diagnostics, pharmaceutical manufacturing, academic research, and industrial quality-control activity. Demand is more concentrated in routine optical systems, pathology, pharmaceutical inspection, and university laboratories than in the highest-end electron microscopy configurations. Foreign-exchange volatility, limited specialist staffing, and less extensive service infrastructure can increase the effective ownership cost of advanced systems, making distributor capability and application training important commercial variables.

Middle East and Africa

Middle East and Africa remains an emerging market, with demand anchored in healthcare modernization, diagnostic laboratory investment, research-university development, and pharmaceutical manufacturing initiatives. Saudi Arabia, the UAE, and South Africa are important focal points. Diagnostic microscopy often provides the first installed base from which suppliers can expand into higher-value research and industrial applications. Growth is constrained by specialist availability, procurement budgets, and the need for dependable local maintenance and training.

China remains commercially important but introduces a distinct portfolio risk for suppliers serving sensitive technologies. Oxford Instruments reported a £302 million order-book reduction associated with its exit from sensitive Chinese market areas ^{[8]Oxford Instruments plc, Annual Report 2024, 2024, oxinst.com}. This demonstrates that regional opportunity cannot be assessed only through demand indicators; export-control exposure and product eligibility can materially alter the accessible market. Diversified positions across South Korea, Japan, Taiwan, India, Australia, and Southeast Asia can reduce dependence on a single regulatory environment.

Microscopy Market Share & Competitive Landscape

Competition is concentrated in premium electron, confocal, semiconductor-metrology, and advanced analytical platforms, while routine optical microscopy remains more fragmented. Differentiation depends on resolution, application-specific workflow design, detector and software integration, service coverage, and the ability to support increasingly complex sample-to-data processes.

Bruker Corporation

Bruker expanded its microscopy and spatial-biology portfolio through several 2024 transactions. It acquired Nion in January, adding aberration-corrected STEM capabilities ^{[6]Bruker Corporation, Bruker Acquires Electron Microscopy Company Nion, January 2024, ir.bruker.com}; Nanophoton in February, adding Raman microscopy ; and Phasefocus in March, adding label-free live-cell imaging . In May 2024, Bruker completed its NanoString asset acquisition for approximately USD 392.6 million, encompassing nCounter, GeoMx, CosMx, and AtoMx product lines . The portfolio broadens Bruker's ability to link molecular, cellular, and ultrastructural analysis.

Carl Zeiss AG

ZEISS combines a large installed base in optical systems with investment in advanced imaging development. Its fiscal 2024/25 group revenue reached EUR 11.896 billion, including EUR 2.334 billion from Industrial Quality & Research ^{[2]Carl Zeiss AG, ZEISS Concludes Fiscal Year 2024/25 with Solid Growth, 2025, zeiss.com}. Lightfield 4D integration with the LSM 910 and LSM 990 platforms supports high-speed volumetric imaging for neuroscience, cancer research, developmental biology, and plant sciences . Its competitive position rests on the ability to extend proven confocal ecosystems rather than requiring customers to adopt entirely separate imaging platforms.

Nikon Corporation

Nikon participates across widefield, stereo, digital, confocal, and multiphoton microscopy. Its AX/AX R platforms target drug-discovery users that require broad field of view, high-resolution imaging, and automated plate-based workflows . The company's opportunity is strongest where laboratories seek standardized imaging pipelines that can operate across discovery, live-cell imaging, and complex biological models.

Thermo Fisher Scientific Inc.

Thermo Fisher's Analytical Instruments segment reported USD 7.463 billion in 2024 revenue ^{[1]Thermo Fisher Scientific, Fourth Quarter and Full Year 2024 Financial Results, February 2025, ir.thermofisher.com}. The company launched the Thermo Scientific Iliad STEM in 2024 and offers the Phenom XL G2 SEM . Its scale in electron microscopy, consumables, and service allows it to compete on workflow continuity and lifecycle support as well as instrument capability.

JEOL Ltd.

JEOL reported fiscal 2024 net sales of JPY 174.3 billion and operating profit of JPY 27.5 billion . Its strategic emphasis on semiconductor development, drug discovery, and battery research aligns its electron microscopy portfolio with applications that require high-resolution structural and compositional analysis ^{[3]JEOL Ltd., Integrated Report 2024, 2024, jeol.com}. This positioning is particularly relevant in Asia Pacific semiconductor and materials ecosystems.

Hitachi High-Tech Corporation

Hitachi High-Tech reported JPY 821.7 billion in Measurement & Analysis Systems revenue in the fiscal year ended March 2026 ^{[4]Hitachi High-Tech Corporation, Company Financial Data and Corporate Profile, 2026, hitachi-hightech.com}. Its CD-SEM capabilities support semiconductor process control, while the SU9600 expands its ultrahigh-resolution SEM offering . The company benefits from proximity to Asian semiconductor supply chains and from its ability to serve both research and production-oriented inspection requirements.

Evident Corporation (Olympus)

Evident was formed from Olympus's Scientific Solutions Division on April 1, 2022, and acquired by Bain Capital Private Equity in April 2023 . The company employs more than 4,300 people across 24 countries and draws on more than a century of Olympus optics heritage . Its broad biological, clinical, and industrial microscopy offering provides an established platform for serving routine and mid-range optical microscopy users.

Keyence Corporation

Keyence reported JPY 1.059 trillion in net sales for the fiscal year ended March 2025, up 9.5% year over year . Its VHX-X1 digital microscope series supports industrial quality control and failure analysis through motorized operation, 4K imaging, elemental analysis, and a 300 mm stage . Its direct-sales model can be an advantage where end users require rapid application demonstrations and configuration support.

Oxford Instruments

Oxford Instruments reported £470.4 million in revenue for the fiscal year ended March 2024 ^{[8]Oxford Instruments plc, Annual Report 2024, 2024, oxinst.com}. Its portfolio includes Asylum Research AFM, WITec confocal Raman microscopy, Andor scientific cameras, and NanoAnalysis products. The company's exposure to academic and government research funding supports demand, while its withdrawal from sensitive Chinese market areas shows the trade-off between addressable revenue and regulatory risk .

Lasertec Corporation

Lasertec specializes in photomask and wafer-defect inspection systems for semiconductor manufacturing. It reported JPY 251.5 billion in net sales for the fiscal year ended June 2025, up 17.8% year over year . Its competitive position is tied to the technical requirements of EUV photomask inspection and the adoption pace of high-NA EUV lithography by semiconductor customers.

Recent Industry Developments

Bruker portfolio acquisitions, 2024: Bruker acquired Nion in January 2024, Nanophoton in February, and Phasefocus in March, extending its presence in aberration-corrected STEM, Raman microscopy, and label-free live-cell imaging ,. The company completed its NanoString asset acquisition in May 2024 for approximately USD 392.6 million .

Thermo Fisher Iliad STEM launch, 2024: Thermo Fisher launched the Thermo Scientific Iliad scanning transmission electron microscope for integrated advanced-materials analysis workflows in 2024 .

ZEISS Lightfield 4D integration: ZEISS integrated Lightfield 4D with its LSM 910 and LSM 990 confocal platforms to enable high-speed volumetric imaging of living specimens .

AOscopy project award, 2025: The European Innovation Council awarded AOscopy under the EIC Transition mechanism in April 2025. The project began in June 2025 and is scheduled to run through May 2028, developing adaptive-optics-enhanced multiphoton microscopy for deep-tissue imaging .

Cryo-EM performance demonstration, 2025: A study published in July 2025 demonstrated sub-3 Å single-particle cryo-EM protein structure determination at 100 keV across samples from 50 kDa apoferritin to a 3.9 MDa AAV9 capsid .

Hitachi High-Tech SU9600 introduction, 2025: Hitachi High-Tech introduced the SU9600 ultrahigh-resolution scanning electron microscope in October 2025 .